Therapeutics News and Research

RSS

Ampio completes patient enrollment in dose-escalation run-in study of Ampion for treatment of knee osteoarthritis

Ampio Pharmaceuticals, Inc. today announced the completion of patient enrollment in a dose-escalation run-in study to a Phase III pivotal trial evaluating Ampion in the treatment of moderate to severe osteoarthritis of the knee.

26 Apr 2013

Scioderm completes Series A financing commitment totaling $16 million

Scioderm, a company developing novel dermatology therapeutics, today announced the completion of a Series A financing commitment totaling $16 million. Morgenthaler Ventures led the Series A financing, with Technology Partners as the second investor participating in the round.

26 Apr 2013

Study shows chemoresponse assay improves survival rates in women with ovarian cancer

This spring, a team of researchers has released results from an eight-year study that shows improved survival rates for women diagnosed with ovarian cancer who undergo cancer tumor testing to determine the best treatment.

26 Apr 2013

Orexigen Therapeutics praises new research report on obesity prevention policies

Orexigen commends CEO as well as the author of the report, Alex Brill , and the Robert Wood Johnson Foundation (RWJF) who funded the report, for this new research illustrating the importance of long-term budget impact analyses on preventive health policies, specifically those aimed at obesity.

26 Apr 2013

Annual scientific symposium of the Cardiovascular Research Foundation celebrates its 25th anniversary

Media registration is now open online for TCT 2013 (Transcatheter Cardiovascular Therapeutics), the annual Scientific Symposium of the Cardiovascular Research Foundation. Celebrating its 25th anniversary this year, the theme of TCT 2013 is envisioning the future, with a focus on innovation in medicine and technology.

26 Apr 2013

LINCC Initiative to provide charitable contribution to 16 organizations to support individuals with HIV/AIDS

Janssen Therapeutics, Division of Janssen Products, LP, today announced the 16 organizations that will receive a charitable contribution from its Linking In-Need Communities to Care Initiative.

25 Apr 2013

Hospital for Special Surgery receives grant for new genomics center to study autoimmune diseases

Hospital for Special Surgery in New York City has received a $5.6 million grant from The Tow Foundation to establish the Hospital for Special Surgery Genomics Center.

25 Apr 2013

Nanogels to attack lupus: an interview with Dr Look and Dr Fahmy, Yale University

Nanogels are synthetic particles that can be used for drug delivery. They are approximately 100 nm to 200 nm in diameter, and are made from safe, biocompatible materials: a gel-like interior and a lipid exterior.

24 Apr 2013

Isis Pharmaceuticals starts ISIS-SMNRx Phase 2 study in infants with SMA

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy. SMA is a severe and rare genetic neuromuscular disease characterized by muscle atrophy and weakness and is the most common genetic cause of infant mortality.

24 Apr 2013

CNIO researcher-led consortium to receive MRA grant to advance research in melanoma

A consortium led by the Spanish National Cancer Research Centre's researcher Mar-a S. Soengas −Programme Director of the Centre-s Molecular Pathology Programme and Leader of the CNIO Melanoma Group− has been selected to receive funding from the Melanoma Research Alliance, the most important private international melanoma research foundation, in order to advance research in melanoma; this type of skin tumour represents one of oncology's biggest challenges due to its high incidence and malignancy.

24 Apr 2013

Animal models of Huntington's disease allow better insights into disease's genetics

Scientific progress in Huntington's disease (HD) relies upon the availability of appropriate animal models that enable insights into the disease's genetics and/or pathophysiology.

23 Apr 2013

Scientists discover new agent that removes potentially dangerous cells

Pluripotent stem cells can turn, or differentiate, into any cell type in the body, such as nerve, muscle or bone, but inevitably some of these stem cells fail to differentiate and end up mixed in with their newly differentiated daughter cells.

23 Apr 2013

Phase 1 clinical study of rHIgM22 initiated for treatment of multiple sclerosis

Mayo Clinic and Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in the first clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis.

23 Apr 2013

DecImmune and DSM to develop proprietary antibody therapeutic

DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed an agreement with venture capital funded DecImmune Therapeutics of Cambridge, Massachusetts, USA.

22 Apr 2013

Genetic study defines link between primary sclerosing cholangitis and other autoimmune diseases

Researchers have newly associated nine genetic regions with a rare autoimmune disease of the liver known as primary sclerosing cholangitis (PSC). This brings the total number of genetic regions associated with the disease to 16.

22 Apr 2013

Monoclonal antibody inhibits tumor growth in angiosarcoma and breast cancer

A monoclonal antibody targeting a protein known as SFPR2 has been shown by researchers at the University of North Carolina to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma.

20 Apr 2013

Civitas Therapeutics reports positive results from Phase 2 study of CVT-301 for Parkinson's disease

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS respiratory delivery platform, today announced positive topline results from a Phase 2 clinical trial of CVT-301, an inhaled formulation of levodopa (L-dopa).

20 Apr 2013

SironRX completes enrollment in Cohort 1 to study JVS-100 for wound healing, scar prevention

SironRX Therapeutics Inc., a privately-held, clinical-stage biotechnology company developing novel regenerative therapies to prevent scarring and promote dermal wound repair, is pleased to report that it has completed enrollment of patients in Cohort 1 of its placebo-controlled, randomized, dose escalation double-blind clinical study evaluating the safety and efficacy of JVS-100 to reduce scar formation and improve wound healing in patients receiving surgical sternotomy incisions.

19 Apr 2013

Targacept moving forward with Phase 2b study of TC-5619 for treatment of schizophrenia

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced that it has completed recruitment of patients in the Phase 2b study of TC-5619 as a treatment for negative symptoms and cognitive dysfunction in schizophrenia.

19 Apr 2013

Patient enrollment underway in Phase III trial program to evaluate amikacin inhalation solution

Bayer HealthCare Pharmaceuticals Inc. announced today that patient enrollment is underway in its global Phase III trial program to evaluate the efficacy and safety of adjunctive aerosolized BAY41-6551 versus aerosolized placebo in the treatment of intubated and mechanically ventilated patients with Gram-negative pneumonia receiving standard of care intravenous antibiotics.

19 Apr 2013

Therapeutics News and Research

Ampio completes patient enrollment in dose-escalation run-in study of Ampion for treatment of knee osteoarthritis

Scioderm completes Series A financing commitment totaling $16 million

Study shows chemoresponse assay improves survival rates in women with ovarian cancer

Orexigen Therapeutics praises new research report on obesity prevention policies

Annual scientific symposium of the Cardiovascular Research Foundation celebrates its 25th anniversary

LINCC Initiative to provide charitable contribution to 16 organizations to support individuals with HIV/AIDS

Hospital for Special Surgery receives grant for new genomics center to study autoimmune diseases

Nanogels to attack lupus: an interview with Dr Look and Dr Fahmy, Yale University

Isis Pharmaceuticals starts ISIS-SMNRx Phase 2 study in infants with SMA

CNIO researcher-led consortium to receive MRA grant to advance research in melanoma

Animal models of Huntington's disease allow better insights into disease's genetics

Scientists discover new agent that removes potentially dangerous cells

Phase 1 clinical study of rHIgM22 initiated for treatment of multiple sclerosis

DecImmune and DSM to develop proprietary antibody therapeutic

Genetic study defines link between primary sclerosing cholangitis and other autoimmune diseases

Monoclonal antibody inhibits tumor growth in angiosarcoma and breast cancer

Civitas Therapeutics reports positive results from Phase 2 study of CVT-301 for Parkinson's disease

SironRX completes enrollment in Cohort 1 to study JVS-100 for wound healing, scar prevention

Targacept moving forward with Phase 2b study of TC-5619 for treatment of schizophrenia

Patient enrollment underway in Phase III trial program to evaluate amikacin inhalation solution

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News